Mandara Biopharma

Mandara Biopharma is a clinical-stage biotechnology company based in India that specializes in the development of novel Chimeric Antigen Receptor T-cell (CAR-T) therapies. Founded by pioneers from the Indian Institute of Technology (IIT) Bombay, the company focuses on creating affordable and accessible cell therapies for hematological malignancies and solid tumors. Their lead research programs target validated antigens such as CD19 and BCMA, utilizing proprietary manufacturing processes designed to significantly lower production costs. Mandara Biopharma operates within a specialized ecosystem of cell therapy innovation, aiming to bridge the gap between advanced genetic engineering and patient care in emerging markets. The company's platform emphasizes safety, efficacy, and scalability to meet the global demand for next-generation immunotherapies.